Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers

Journal of the National Cancer Institute

Volumn 104, Issue 12, 2012, Pages 953-956

  Mukherjee, Bhramar ^a   Delancey, John Oliver ^a   Raskin, Leon ^a   Everett, Jessica ^a   Jeter, Joanne ^b   Begg, Colin B ^c   Orlow, Irene ^d   Berwick, Marianne ^e   Armstrong, Bruce K ^f   Kricker, Anne ^f   Marrett, Loraine D ^g   Millikan, Robert C ^h   Culver, Hoda Anton ⁱ   Rosso, Stefano ⁱ   Zanetti, Roberto ^j   Kanetsky, Peter A ^k   From, Lynn ^k   Gruber, Stephen B ^a,l  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f CANCER CARE ONTARIO   (Canada)

^g The University of North Carolina at Chapel Hill   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Piedmont Cancer Registry   (Italy)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k WOMEN S COLLEGE HOSPITAL   (Canada)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER LOCALIZATION; CANCER RISK; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MENDELIAN RANDOMIZATION ANALYSIS; NEPHROBLASTOMA; PANCREAS CANCER; PRIORITY JOURNAL; RELATIVE; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84864143250     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs221     Document Type: Article

References (27)

1. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma . Nat Genet. 1994; 8 (1): 15-21. (Pubitemid 24274055)
2. Debniak T, Scott RJ, Huzarski T, et al. CDKN2A common variant and multi-organ cancer risk-a population-based study. Int J Cancer. 2006; 118 (12): 3180-3182.
3. Oldenburg RA, de Vos tot Nederveen Cappel WH, van Puijenbroek M, et al. Extending the p16-Leiden tumour spectrum by respiratory tract tumours. J Med Genet. 2004; 41 (3): e31.
4. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations . N Engl J Med. 1995; 333 (15): 970-974.
5. Hille ET, van Duijn E, Gruis NA, Rosendaal FR, Bergman W, Vandenbroucke JP. Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994. J Invest Dermatol. 1998; 110 (5): 788-792. (Pubitemid 28194029)
6. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specifi c 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000; 87 (6): 809-811. (Pubitemid 30660559)
7. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000; 92 (15): 1260-1266. (Pubitemid 30627734)
8. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA. Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet. 2004; 41 (6): 421-424. (Pubitemid 38788036)
9. Debniak T, Gorski B, Huzarski T, et al. A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet. 2005; 42 (10): 763-765. (Pubitemid 41475251)
10. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006; 66 (20): 9818-9828. (Pubitemid 44672032)
11. Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer. 2008; 7 (4): 331-337.
12. Vinarsky V, Fine RL, Assaad A, et al. Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck. 2009; 31 (11): 1524-1527.
13. Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 infl uences childhood acute lymphoblastic leukemia risk. Nat Genet. 2010; 42 (6): 492-494.
14. Cust AE, Harland M, Makalic E, et al. Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. J Med Genet. 2011; 48 (4): 266-272.
15. Begg CB, Berwick M. A note on the estimation of relative risks of rare genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev. 1997; 6 (2): 99-103. (Pubitemid 27069202)
16. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotypephenotype relationships in U.S. melanomaprone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst. 2000; 92 (12): 1006-1010. (Pubitemid 30469967)
17. Begg CB, Hummer AJ, Mujumdar U, et al. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol. 2006; 35 (3): 756-764. (Pubitemid 43985574)
18. Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev. 2006; 15 (8): 1520-1525. (Pubitemid 44299326)
19. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005; 97 (20): 1507-1515. (Pubitemid 41631950)
20. Wacholder S, Hartge P, Struewing JP, et al. The kin-cohort study for estimating penetrance. Am J Epidemiol. 1998; 148 (7): 623-630. (Pubitemid 28498429)
21. Gail MH, Pee D, Carroll R. Kin-cohort designs for gene characterization. J Natl Cancer Inst Monogr. 1999;(26): 55-60.
22. Moore DF, Chatterjee N, Pee D, Gail MH. Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study. Genet Epidemiol. 2001; 20 (2): 210-227. (Pubitemid 32106138)
23. Chatterjee N, Wacholder S. A marginal likelihood approach for estimating penetrance from kin-cohort designs. Biometrics. 2001; 57 (1): 245-252. (Pubitemid 32200163)
24. de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008; 14 (21): 7151-7157.
25. McWilliams RR, Wieben ED, Rabe KR, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2011; 19 (4) : 472-478.
26. Cust AE, Schmid H, Maskiell JA, et al. Population-based, case-control-family design to investigate genetic and environmental infl uences on melanoma risk: Australian Melanoma Family Study. Am J Epidemiol. 2009; 170 (12): 1541-1554.
27. Ziogas A, Anton-Culver H. Validation of family history data in cancer family registries. Am J Prev Med. 2003; 24 (2): 190-198. (Pubitemid 36144098)